We have previously shown that the anti-apoptotic transcription factor, Brn-3a and the pro-apoptotic p53 factor have antagonistic effects on the promoter of the gene encoding the anti-apoptotic Bcl-2 protein, with p53 abolishing activation by Brn-3a. Here we demonstrate that this antagonism is also observed on the gene encoding the pro-apoptotic Bax protein with Brn-3a abolishing the ability of p53 to activate the Bax promoter and induce Bax protein expression. In contrast, Brn-3a and p53 cooperative to induce maximal activation of another p53 target gene encoding the cyclin dependent kinase inhibitor, p21 CIP1/Waf1 . These differential effects of Brn-3a on p53-inducible genes involved in apoptosis or growth arrest are paralleled by its effects on these processes themselves. Thus, we show that Brn-3a antagonises the anti-apoptotic effect of p53 but co-operates with p53 to induce cell cycle arrest. The potential role of Brn-3a in determining the outcome of enhanced p53 levels is discussed.
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Keywords: Brn-3a; p53; neuronal cells; apoptosis; cellcycle arrest During development, apoptosis or programmed cell death plays a critical role in determining the number of neurones innervating target areas with extensive cell death occurring in the areas of the brain and spinal ganglia where proliferative neuroblasts are ceasing to divide and undergo differentiation into non-dividing neurones (Hamburger et al., 1981; Savitz and Rosenbaum, 1998; D'Mello, 1998) . Subsequently, a number of more mature neurones also undergo apoptosis and their fate is determined by external factors such as the limited supply of trophic factors derived from the target field e.g. nerve growth factor (NGF), neurotrophin-3 (NT-3), brain derived neurotrophic factor (BDNF) and cyclic AMP (Sieber-Blum, 1998) . Apoptosis also play an important role in some pathological conditions such as response to neuronal injury or in neurodegenerative diseases (Savitz and Rosenbaum, 1998) .
The precise mechanisms which underlie the commitment of neurones to differentiate or undergo apoptosis are still unclear but a number of proteins have been identified which modify these responses in neuronal cells and thus have been implicated in this process. For example, the p53 protein is associated with apoptosis or differentiation in different cell types including neuronal cells (Ko and Prives, 1996; Eizenberg et al., 1996) . A transient increase in the expression of p53 mRNA and protein was demonstrated in migrating neurones and this decreased upon differentiation (Eizenberg et al., 1996; Hughes et al., 1997) . Extensive studies carried out to understand mechanisms underlying p53 mediated effects on cells have shown that upon induction of expression and activation by posttranscriptional effects such as phosphorylation, this protein may either give rise to cell cycle arrest or induce apoptosis depending on the cell type and growth conditions (Ko and Prives, 1996) . It is still not entirely clear what factors determine whether a cell undergoes cell cycle arrest or apoptosis upon induction of p53 expression. However, in the presence of survival factors such as growth factors in serum, p53 expression results in cell cycle arrest, thus allowing for differentiation or DNA repair following DNA damage (Ko and Prives, 1996) . This cell cycle arrest is associated with increased expression of specific p53 regulated genes including the cyclin-dependent kinase inhibitor, p21 CIP1/Waf1 (el Deiry et al., 1993) . In contrast, in the absence of serum/growth factors or in the presence of cytotoxic agents, induction of p53 results in apoptosis (Deckwerth et al., 1996) . This is associated with p53-induced activation of the pro-apoptotic Bcl-related factor, Bax (Miyashita and Reed, 1995) and reduced expression of the anti-apoptotic Bcl-2 protein (Miyashita et al., 1994) . Hence under these conditions, induction of p53 results in an increased ratio of proapoptotic to anti-apoptotic Bcl-2 family proteins with consequent enhanced apoptosis.
We have previously demonstrated that the POU family transcription factor, Brn-3a, which is upregulated by cyclic AMP in neuronal cells (BudhramMahadeo, 1994 ) exerts an anti-apoptotic effect to promote neuronal survival both in vitro and in vivo and can strongly activate the Bcl-2 promoter (Smith et al., 1998; Ensor et al., 2001) . Moreover, we have shown that wild type p53 interacts with Brn-3a via a direct protein -protein interaction and antagonizes the ability of Brn-3a to transactivate the Bcl-2 promoter so that in the presence of both proteins, no transactivation is observed (Budhram-Mahadeo et al., 1999) .
Brn-3a belongs to the POU domain family of transcriptional regulators which were identified on the basis of sequence homology in the highly conserved POU domain of the original members, the mammalian transcription factors Pit-1, Oct-1 and Oct-2 and the nematode regulatory gene Unc-86 (for review see Verrijzer and van der Vliet, 1993; Ryan and Rosenfeld, 1997) . A number of target promoters regulated by Brn3a have been identified including neuronal specific promoters such as those of the genes encoding ainternexin (Budhram-Mahadeo et al., 1995) , synaptophysin (Smith et al., 1997a) and SNAP-25 as well as the promoter of the anti-apoptotic Bcl-2 factor (Smith et al., 1998) .
Brn-3a was originally identified in the developing and adult nervous system with localization to specific regions of the brain, sensory ganglia and the retina (He et al., 1989; Lillycrop et al., 1992; Gerrero et al., 1993) . Interestingly, mice in which Brn-3a has been deleted by homologous recombination show extensive loss of somato-sensory neurones with resulting death of the homozygous mice soon after birth (McEvilly et al., 1996; Xiang et al., 1996) suggesting a key role for Brn3a in the development/survival of specific neuronal cells. In agreement with this idea, we have shown that over-expression of Brn-3a, enhances the survival both of a neuronal cell line and of cultured dorsal root and trigeminal ganglion neurones upon removal of neurotrophic factors. In contrast, reduction of Brn-3a expression using an anti-sense approach results in apoptosis of these neurones even in the presence of neurotrophic factors (Smith et al., 1998; Ensor et al., 2001) . Moreover, using a model of neonatal sciatic nerve crush, we have shown that over-expression of Brn-3a can also enhance neuronal survival in vivo .
As well as these effects upon neuronal survival, Brn3a also appears to exert specific effects upon neuronal differentiation. Thus, Fedtsova and Turner (1995) demonstrated that Brn-3a expression can be used as a marker of the earliest post-mitotic neurones. Similarly, we have demonstrated that in neuronal cell lines, Brn3a expression is greatly increased when the cells are induced to differentiate from a proliferating phenotype to a non-dividing, differentiated cell with neurite outgrowth (Lillycrop et al., 1992; Smith et al., 1997b) . Moreover, over-expression of Brn-3a in these neuronal cells can induce the expression of neuronalspecific genes and neurite outgrowth under conditions where this would not normally occur (Smith et al., 1997b) . That Brn-3a is required for outgrowth of neuronal process has recently been confirm in Brn-3a knock out mice. Thus these mice display defects in neurite outgrowth which is independent of any effects on neuronal survival (Eng et al., 2001) .
Brn-3a therefore represents a transcription factor, which can induce both enhanced neuronal survival and enhanced neuronal differentiation. This is in contrast to p53, which induces differentiation but also promotes apoptosis. Moreover, we have previously demonstrated that upon interaction Brn-3a and p53 antagonize one another on the Bcl-2 promoter (Budhram-Mahadeo et al., 1999) . Thus, whilst Brn3a strongly induces the Bcl-2 promoter, this effect is abolished by p53 resulting in no transcriptional induction in the presence of both proteins. This was specific to the Bcl-2 promoter since p53 did not repress, and in fact slightly enhanced, the effect of Brn-3a on the promoter of its neuronal target gene, ainternexin (Budhram-Mahadeo et al., 1995) .
In view of the opposite effects of these factors on apoptosis, and their antagonistic effects on the Bcl-2 promoter, we were interested in studying the effect of Brn-3a/p53 interaction on the ability of Brn-3a to modulate cell survival and differentiation. In particular, we wish to determine whether, as in the case of Bcl-2 gene expression, the effect of p53 would override the protective effects of Brn-3a. For these studies on cell survival, we utilized the neuronal-derived cell line, ND7, which provide an in vitro model for neuronal cell growth and differentiation (Wood et al., 1990 ) and which we have previously used to investigate the effects of Brn-3a upon both differentiation and apoptosis (Smith et al., 1998) . These cells were transfected with mammalian expression vectors which allows high expression of Brn-3a and/or p53 or with empty expression vector lacking any insert. To measure the survival of transfected cells, a vector encoding the reporter gene, green fluorescent protein (GFP) was included in all transfections to identify the transfected cells. Forty-eight hours following transfection, cells were harvested and the number of surviving transfected cells expressing GFP was measured by flow cytometry and fluorescence-activated cell sorting (FACS) analysis.
As expected, cell expressing Brn-3a showed somewhat better survival than control cells transfected with empty LTR vector alone ( Figure 1a ). In contrast, cells transfected with p53 showed marginally reduced survival compared to control cells which is also expected. Most interestingly however, transfection of Brn-3a and p53 together resulted in enhanced survival of the cells which was comparable to or slightly greater than that observed with Brn-3a alone and was very different from the survival observed with p53 ( Figure  1a ).
To confirm that these differences in cell survival upon co-expression of Brn-3a and p53 resulted from decreased death, we also measured apoptosis in the transfected cells using annexin V labelling which recognizes modified phosphatidylserine on the surface of apoptotic cells. In these studies, we obtained results that supported the data obtained by measuring cell survival. Thus, using this assay, the number of apoptotic cells observed following transfection of Brn3a and p53 together was similar to that observed with Brn-3a alone and considerably lower than that observed with p53 alone (Figure 1b) . Hence, in the presence of Brn-3a and p53, the anti-apoptotic effect of Brn-3a overrides the pro-apoptotic effect of p53 resulting in protection from p53 induced cell death.
Since we had previously shown that p53 can block Brn-3a-mediated activation of the Bcl-2 promoter (Budhram-Mahadeo et al., 1999) it was necessary to examine the effect of this interaction on p53 target genes involved in apoptosis to determine the mechanism by which co-expression of Brn-3a and p53 can protect against p53 mediated cell death. We therefore tested the effect of Brn-3a and/or p53 on the promoter of the pro-apoptotic Bax gene, which is strongly induced by p53 (Miyashita and Reed, 1995) and plays a key role in the p53 mediated pro-apoptotic response.
Therefore expression vectors encoding either Brn-3a and/or p53 or the empty LTR control vector were cotransfected into the neuronal cell line, ND7, with a reporter construct in which the Bax promoter drives expression of the luciferase gene. As shown in Figure  2a there was, as expected, strong induction of the Bax promoter by p53. In contrast, Brn-3a alone had a mild inhibitory effect on the promoter activity. However, cotransfection of Brn-3a and p53 together resulted in loss of the p53 mediated stimulation of the Bax promoter with the activity of the promoter now comparable to background activity observed with empty LTR expression vector alone. Therefore, Brn-3a can mildly repress the activity of the Bax promoter but more interestingly, can inhibit the stimulatory effect of p53. This ability of Brn-3a to repress p53 mediated Bax expression may contribute to the protective effect of co-expressing Brn3a and p53, which was seen in survival/apoptosis assays ( Figure 1 ).
Since Brn-3a could negatively regulate the promoter of the p53 target Bax gene, we also examined the effect of Brn-3a on the promoter of the cyclin-dependent kinase inhibitor, p21
, another p53 target gene, which plays a key role in p53-mediated cell cycle arrest (el Deiry et al., 1993) . As before, expression vectors encoding Brn-3a and/or p53 were co-transfected into ND7 cells but with a reporter construct in which the promoter of the p21 CIP1/Waf1 gene drives expression of the luciferase reporter gene. As expected, p53 activated the p21 CIP1/Waf1 promoter ( Figure 2b ). However, in contrast to the effect on the Bax promoter, Brn-3a alone had a clear stimulatory effect on the p21 CIP1/Waf1 a b Figure 1 Effect of over-expressing Brn-3a and p53 alone or together on survival or death of ND7 neuronal cell line (Wood et al., 1990) . ND7 cells, plated at a density of 5610 5 cells, in 10 cm plates were left overnight before transfecting the following morning using the CaPO 4 method (Budhram-Mahadeo et al., 1995) . Cells were transfected with the expression vector containing the cDNA encoding either Brn-3a (Budhram-Mahadeo et al., 1995) or wild type p53 (a kind gift from C Midgley) alone and Brn-3a/p53 together. The empty expression vector was transfected and used as the control to compare the effects of p53 and/ or Brn-3a. An expression vector encoding the green fluorescent protein (GFP) was also co-transfected in all experiments to facilitate the sorting of transfected cells from non-transfected cells. Cells were harvested in 16PBS after 48 h and analysed for GFP positivity. This was quantified using fluorescence-activated cell sorting (FACS) analysis. To measure apoptotic cell death, transfected cells were labelled with Annexin V antibody (Boehringer Mannheim, Germany), according to the manufacturer's protocol and then measured by flow cytometry and FACS analysis. promoter. Moreover, upon co-expression of Brn-3a and p53 together, a strong activation of the promoter was observed which was greater than either Brn-3a or p53 alone (Figure 2b ). Thus while Brn-3a antagonizes p53 effects on the Bax promoter, it co-operates with p53 to strongly stimulate the p21 CIP1/Waf1 promoter. These results therefore clearly demonstrate that the interaction of Brn-3a and p53 proteins can result in the differential regulation of different p53 target gene promoters.
Since the effects of Brn-3a on these p53 target promoters were so significant, it may be possible to observe the functional effect of these changes in cells which co-expressed both Brn-3a and p53 compared with either protein alone. We tested this by analysing for the levels of the Bax and p21 CIP1/Waf1 proteins in ND7 cells transfected with Brn-3a and/or p53 compared with the control empty vector. These experiments were feasible since it is possible to achieve high transfection efficiencies of over 50% in ND7 cells. With this high level of transfection coupled with the strong effects of co-expressing Brn-3a/p53 on the Bax and p21
CIP1/Waf1 promoters, we hoped to detect changes in protein level even though not all cells in the culture would be transfected. Thus, ND7 cells were transfected with expression vectors which encoded for Brn-3a and p53 alone and together, as described before. After 48 h, cells were harvested then subjected to SDS -PAGE and Western blotting with antibodies that recognize Bax and p21 CIP1/Waf1 (Figure 3 , panels 2 and 3). Variations in the levels of total protein in different samples were corrected by measuring and adjusting for the level of the invariant protein, actin (Figure 3, panel 4) . We also demonstrated that the cells overexpressed the transfected Brn-3a transcription factor (Figure 3, panel 1) .
As illustrated in Figure 3 (panels 2 and 3), the coexpression of Brn-3a and p53 in these cells resulted in changes in the levels of Bax and p21 CIP1/Waf1 proteins. Thus, as expected, transfection of p53 alone resulted in a clear upregulation of Bax expression compared with levels in cells transfected with Brn-3a alone or in the control cells. Moreover, the induction of this protein by p53 was lost upon co-transfection of Brn-3a and p53 (Figure 3, panel 3) , which supportes the antagonistic effects of the Brn-3a on p53 mediated activation of the Bax promoter.
In contrast, analysis of p21 CIP1/Waf1 protein in these samples (panel 3) showed that, as predicted from the co-operative effect of Brn-3a and p53 on the promoter, a b Figure 2 Effect of Brn-3a and/or p53 on p53 target promoters driving expression of (a) bax or (b) p21 cip1/waf1 . Reporter constructs in which the Bax or p21 cip1/waf1 promoter drives expression of the firefly luciferase reporter gene (kind gifts from Dr J Reed and Dr W El Diery respectively) were co-transfected with the expression vector containing the cDNA encoding either Brn-3a and/ or wild type p53 or the empty vector into ND7 cells, as described above. The renilla reporter plasmid (1 : 10 ratio of target receptor) was also included in all experiments to control for variation in transfection efficiency. Cells were harvested after 48 h and assayed for luciferase activity. All values were equalized on the basis of the activity observed upon co-transfection with a control renilla expression vector and expressed as a percentage of the empty protein expressed in cells co-transfected with both Brn3a and p53 compared with either factor alone. Thus, Brn-3a and p53 can enhance the activity of the p21 CIP1/ Waf1 promoter and this is reproduced at the protein level also. However, in this model, in which we used proliferating ND7 cells, p53 expression alone could strongly activate Bax but not p21 CIP1/Waf1 expression. This is interesting as we had previously shown that under these proliferative conditions, Brn-3a is expressed at low levels in ND7 cells (O'Mello, 1998). Thus, it appears that transfection of p53 alone in proliferating cells with low endogenous Brn-3a levels, results in increased expression of pro-apoptotic targets such as Bax leading to increased cell death. This observation supports the evidence shown in Figure 1a ,b. However, under these conditions, p53 does not appear to appreciably change the level of p21 CIP1/Waf1 , associated with cell cycle arrest, since maximal levels of p21 CIP1/Waf1 protein was only seen in cells expressing high levels of both Brn-3a and p53. These results suggest that in these cells, Brn-3a expression is important for determining the p53 target genes that are expressed and the consequent effect on cell fate.
The strong co-operative effect of Brn-3a and p53 on the promoter activity and levels of the p21 CIP1/Waf1 protein is very interesting as it is known that increased p21 CIP1/Waf1 is associated with cell cycle arrest. It is therefore possible that co-expression of Brn-3a and p53 may enhance cell cycle arrest, which precedes differentiation. This is of particular interest in this study, as Brn-3a over-expression is known to induce differentiation of ND7 cells (Smith et al., 1997b) . Since we have shown that Brn-3a can directly activate the p21 CIP1/ Waf1 promoter as well as co-operate with p53 with resultant enhanced activity reflected in increased protein expression, we wish to investigate whether their co-expression altered the cell cycle profile of these cells.
Therefore we tested the effect of co-expression of Brn-3a and p53 on cell cycle arrest by transfecting ND7 cells with Brn-3a and/or p53 alone or together. GFP reporter construct was included in all experiments to mark transfected cells. As before, the empty vector was used as the control. The transfected cells expressing GFP were sorted from the non-transfected cells and stained with Hoechst dye to facilitate determination of their cell cycle profile by FACS analysis. Figure 4 demonstrates a typical cell cycle profile obtained in these experiments while Table 1 shows the mean value obtained in four independent experiments. The values represent the percentage of cells in different phases of the cell cycle (sub-G, G0/G1, S and G2/M phase) and the G0/G1 : S phase ratio (which indicate the relative changes in cell cycle progression in each transfected cell population compared with the control vector alone).
In these experiments, there was less cell death (sub-G1) in cells transfected with Brn-3a or Brn-3a and p53 compared with p53 alone or the vector control. This is as expected since we had previously shown that Brn-3a protects these cells from apoptosis while the effects of Brn-3a/p53 interaction confirm other findings in this study. However, a larger proportion of cells cotransfected with both Brn-3a and p53 were in the G0/G1 phase of the cell cycle compared with the percentage of the cell transfected with Brn-3a alone, p53 alone, or the vector control. This pattern was not observed when looking at the percentage of the different transfected cells in S or G2/M phases of the cell cycle. Thus there were no significant differences in S phase in cells co-expressing Brn-3a and p53 CIP1/Waf1 and Bax protein assayed by Western blotting in ND7 cells transfected with Brn-3a and/or p53 or with vector alone. The levels of Brn-3a itself and of the control actin protein are shown in each transfected cell population for comparison. Following transfection, cells were washed with 16PBS, lysed in 26Laemelli buffer and protein prepared as described in Budhram-Mahadeo et al. (1999) . Samples were run on a 12.5 or 15% PAGE gel, transferred onto Hybond C membrane (Amersham) and then incubated with antibodies against Brn-3a (SC8429-Santa Cruz) (1 : 1000); p21 CIP1/Waf1 (Ab4-Oncogene Sciences) (1 : 200) and Bax (Ab6-Oncogene Sciences) (1 : 200). Actin levels were used to equalise for variation in protein loading in different samples using anti-actin antibody (Santa Cruz Biotechnology) (1 : 1500). Following incubation with HRP conjugated secondary antibodies (DAKO anti-mouse and anti-goat) signal was detected by enhanced chemiluminescence (Amersham International)
Brn-3a differentially regulates p53 V Budram-Mahadeo et al compared with p53 or Brn-3a alone while the percentage of cells with Brn-3a and p53 which were in G2/M was similar to that observed with p53 alone (Table 1) . The G0/G1 : S ratio, which represents the change in the proportion of cells progressing through the cell cycle, was lowest in cells co-expressing Brn-3a and p53. This indicates that fewer cells are transiting the G0/G1 boundary into S phase in the presence of both Brn-3a and p53 compared with either protein alone or in the vector control.
This increased proportion of cells G0/G1 upon coexpression of Brn-3a and p53 is not simply dependent on the reduced cell death occurring in these cells since there are more cells in G0/G1 upon co-transfection with Brn-3a and p53 together, compared to Brn-3a alone whereas the extent of cell death is comparable (Table 1) . Moreover, this effect is specific for G0/G1 as no enhancement is observed in the proportion of S phase or G2/M phase cells transfected with Brn-3a and p53 together compared to the other treatments. In cells transfected with p53 and vector there were less viable cells as reflected in the sub G1 peak compared with Brn-3a alone or Brn-3a and p53 together supporting a role for Brn-3a in cell survival also. However, on its own, p53 induces death but no significant cell cycle arrest in these cells. Thus these results have confirmed that in the presence of Brn-3a there is decrease in p53 mediated apoptosis and increased cell cycle arrest.
These findings have indicated an important and relevant role for the interaction of Brn-3a and p53 in events which influence the fate of neuronal cells. This may have implications for neuronal survival and differentiation when there is significant apoptosis such as during development when proliferating neuronal Brn-3a differentially regulates p53 V Budram-Mahadeo et al precursor cells cease dividing and either differentiate to mature neuronal cells or undergo apoptosis, in survival of more mature neurones, following injury or in neurodegenerative diseases. The factors that contribute to neuronal survival and differentiation during development have been widely studied but the precise mechanisms that determine the genes expressed and the resulting cell fate remain to be determined. It is known that the tumour suppressor, p53 is transiently expressed and activated in some neurones as they migrate to their target field and differentiate (Eizenberg et al., 1996; Hughes et al., 1997) . Expression of p53 may result in either cell cycle arrest or apoptosis and this is characterized by expression of different subset of p53 target genes associated with these events. For example, p53 mediated cell cycle arrest is associated with induction of the gene encoding the cyclin-dependent kinase inhibitor p21 CIP1/Waf1 whilst apoptosis is associated with the induction of the proapoptotic proteins, such as Bax, by p53. However, the mechanisms which determine the genes which are activated by p53 in specific temporal or spatial manner and hence the pathway which is followed by the cell are still being studied. We have shown that the Brn-3a transcription factor interacts with p53 via a direct protein -protein interaction (Budhram-Mahadeo et al., 1999) and that these two factors modulate each others' effects on their target genes expression. Thus, we have previously demonstrated that p53 can completely abolish the ability of Brn-3a to activate the promoter of the gene encoding the anti-apoptotic Bcl-2 protein (Budhram-Mahadeo et al., 1999) but not on another Brn-3a target gene promoter, a-internexin. Correspondingly, in the data presented here we have shown that Brn-3a can abolish the ability of p53 to stimulate the promoter of the gene encoding the pro-apoptotic Bax factor.
These results would suggest that the pro-apoptotic effect of p53 and the anti-apoptotic effect of Brn-3a which was have previously demonstrated Smith et al., 2001) should antagonize one another. We have demonstrated that cells co-transfected with Brn-3a and p53 together are protected from apoptosis when compared with both control cells and cells transfected with p53 alone. It seems therefore that, at least in neuronal ND7 cells, the ability of Brn-3a to abolish p53-mediated induction of the Bax promoter is of greater importance in determining apoptosis than the ability of p53 to block activation of the Bcl-2 promoter by Brn-3a. This is in agreement with the finding that in Bcl-2 knock out mice, loss of expression of this protein does not result in enhanced levels of programmed cell death during the normal period of neuronal cell loss (Greenlund et al., 1995; Johnson et al., 1999; Veis et al., 1993) . Thus Bcl-2 expression may not be of importance in the natural period of programmed cell death, although it does apparently play a key role in protecting cells from cell death later in development. However, Bax mediated cell death is critical during neuronal development since loss of Bax protein in knock-out mice does result in increased numbers of neurones in specific ganglia (Eizenberg et al., 1996) . Thus the ability of Brn-3a to suppress Bax expression directly and indirectly by repressing p53 Figure 5 Model for the role of Brn-3a in promoting p53-induced neuronal differentiation and inhibiting p53-induced apoptosis. Thus, expression of Brn-3a which is stimulated by survival factors (Budhram-Mahadeo et al., 1994) would activate expression of anti-apoptotic factors such as Bcl-2 and Bcl-X L while repressing the expression of pro-apoptotic factors such as Bax. In the presence of transiently expressed p53 protein, Brn-3a represses p53 mediated Bax expression but co-operate with p53 to increase p21 CIP1/Waf1 levels with consequent cell survival and cell cycle arrest. Brn-3a can then stimulate the expression of its target differentiation associated genes such as a-internexin, neurofilaments, SNAP-25 etc. In neurones lacking Brn-3a but expressing p53, p53 induction of high levels of pro-apoptotic target genes such as Bax will result in apoptosis. Thus in this neuronal cell model, Brn-3a may play a critical role in determining the p53 pathway that is activated and thus the fate of the cells Brn-3a differentially regulates p53 V Budram-Mahadeo et al mediated expression would suggest that this may be important in determining the survival of Brn-3a expressing neurones.
Interestingly, the ability of Brn-3a to antagonize the induction of the Bax promoter by p53 appears to be a promoter-specific effect since it is not observed in cotransfections using another p53-inducible promoter, that of the gene encoding the cyclin-dependent kinase inhibitor p21 CIP1/Waf1 . Indeed, in this case Brn-3a and p53 co-operate to give rise to stronger induction of the promoter and of the corresponding protein than found with either factor alone. It will evidently be of interest to analyse the molecule structure of the Bax and p21 CIP1/Waf1 promoters to determine the mechanisms responsible for their different responses to co-expression of Brn-3a and p53. However, in terms of the functional role of the interaction of Brn-3a and p53 on the p21 CIP1/Waf1 , it is of particular significance that p21 CIP1/Waf1 plays a key role in the ability of p53 to induce cell cycle arrest (el Deiry et al., 1993) . Moreover, we have previously demonstrated that Brn-3a is also able to induce differentiation in neuronal cells (Smith et al., 1997b) and in this current study we have shown that Brn-3a can directly transactivate the p21 CIP1/Waf1 promoter. However, we have also shown that ND7 cells undergo maximal cell cycle arrest in the G0/G1 phase of the cell cycle when transfected with Brn-3a and p53 together compared to the effect of either factor alone. Hence, although Brn-3a and p53 antagonize one another in their effects on genes regulating apoptosis, they co-operate to induce cell cycle arrest.
This therefore suggests a model ( Figure 5 ) in which Brn-3a may determine the cellular status and survival of neuronal cells which co-express Brn-3a and p53 during development. Thus it is possible that the neurones which express Brn-3a are more likely to survive upon transient expression of p53 during differentiation since these cells will contain higher levels of p21 CIP1/Waf1 and lower levels of Bax. Conversely, in the absence of Brn-3a, p53 expression would induce high levels of Bax with resultant increase in cell death.
The ability of Brn-3a to differentially regulate p53 mediated gene expression is a novel and significant observation since it suggests a possible mechanism by which p53 can produce different effects on cells (differentiation or apoptosis) depending on the presence of other regulatory factors such as Brn-3a which have cell specific expression. Hence, the interaction of Brn-3a and p53 may play a critical role in the survival and differentiation of neuronal cells. Clearly, in surviving cells which express Brn-3a, this transcription factor can then also up-regulate other neuronal genes associated with the differentiated phenotype such as SNAP-25, a-internexin and synaptophysin which are also known targets for this transcription factor. The results presented here may therefore help to elucidate the mechanisms underlying the processes of cell cycle arrest/differentiation and apoptosis, which occur during normal development of the nervous system.
